"Medical Speed Reading Society" Internet Medical Payment Project Determines Global Sky Price Drug Into Japan's Health Insurance

Health and Health Commission issued a clear message on Internet-plus-medical services and fee-paying behavior; WHO: new coronaviruses could become an epidemic virus that will never go away; "the world's most expensive drug" was incorporated into Japan's health insurance coverage, the second ADC treatment drug approved for sale in China ..On May 13th, from 0 to 24 hours, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang Production and Construction Corps reported 3 new confirmed cases, all of which were local cases (2 in Liaoning and 1 in Jilin); (Official website of the National Health and Health Commission)in order to speed up the evaluation of the consistency of generic drugs, the State Drug Administration issued on the 14th "The State Drug Administration on the implementation of chemical injection sufa quality and efficacy consistency evaluation of the work", the drug injection consistency evaluation officially launched(State Drug Administration)14, the State Health and Reform Commission issued a notice on the public medical institutions to do a good job in the "Internet and Medical Services" project technical specifications and financial management workThe notice identifies 10 "Internet plus Medical Services" items and related fee-paying behaviorMichael Ryan, head of WHO's health emergency program, said the new coronavirus could be a long-term problem, and it was difficult to predict when it would be able to beat it, and it could become an epidemic that would never go awayMichael Ryan says he hopes to develop a highly effective vaccine that will be distributed to everyone in the world(People's Daily)According to Kyodo news agency, Japan's Ministry of Health, Labour and Welfare decided on the 13th to "Zolgensma" as the applicable target of public health insurance, the drug price of 1670.7 million yen (about 11.02 million yuan)This is good news for patients and their families waiting for treatment(Kyodo)Kingsley Biotech subsidiary Legendary Bio formally filed an F-1 prospectus with the U.SSecurities and Exchange Commission, with Morgan Stanley, JPMorgan Chase and Jeffery as co-lead underwriters listed on NASDAQ under the "LEGN" trading codeDetails of the proposed offering, including the size and price range, have not yet been finalizedAfter the merger ofAbbVie and Aljian, the new company El Jian Aesthetics announced the latest personnel changes on the 13th: Wang Wei, former president of El Jian China, officially became Vice President of Aerjian Aesthetics on May 9th, head of Japan and Asia Pacific, and will report directly to The President of El Jian Aesthetics International, Shi Jiesheng El Jian Aesthetics belongs to AbbVie's subsidiary (E Pharmaceutical Manager) Huaren Pharmaceuticals issued a notice on the 13th, said that the CEO Shen Hongze for personal reasons to resign from the 6th Board of Directors executive position, resigned after the resignation of no longer in other positions, Vice President Li Xiaoli for personal reasons to apply to resign from the sixth board of directors vice president, resign after the resignation of no longer in other positions Shen Hongze and Li Xiaoli's original terms of office are not yet complete (Seiber Blue) According to enterprise inspection data show that Ali Cloud Computing Co., Ltd business scope has changed, the addition of a second category of medical device sales Data show that Ali Cloud Computing Co., Ltd was established in April 2008, registered capital of 1 billion yuan, the legal representative is Ali Yun Intelligent President Zhang Jianfeng, the company's business scope includes operating telecommunications business, sales of second-class medical devices (Seiber Blue Devices) NMPA official website shows that Takeda Pharmaceutical's domestic application for the injection of Vibutusixima has been approved, becoming the second ADC drug approved for listing in China (NMPA) 14, ASCO official website published this year's General Assembly selected summary content, which Baiji Shenzhou independently developed anti-PD-1 antibody drug Baizean ® combined chemotherapy for the treatment of first-line squamous non-small cell lung cancer (NSCLC) The patient's Phase 3 clinical trial (BGB-A317-307 study) data were disclosed for the first time: Treli-Ju-Ju-dan-injection combined chemotherapy for the treatment of first-line squamous non-small cell lung cancer, compared with traditional chemotherapy programs, has good clinical benefits (Sina Pharmaceutical News) 14, Cinda and Lilly jointly announced: the joint development of the innovative drug PD-1 inhibitor Dabershu ® in a clinical study for advanced esophageal squamous cancer second-line treatment of randomized controlled phase II clinical study reached a preset major research end Sindilli single anti-single drug compared to chemotherapy single-drug treatment, significantly prolonged the total survival and reduced the risk of death, the safety characteristics and the previously reported Sindilli mono-resistance research results consistent, no new safety signals 13, Mersadon announced the results of the keynote-204 clinical trial for the first time, keynote-204 is a Phase 3 clinical trial to evaluate Keytruda's treatment of adult patients with recurrent or refractory classic Hodgkin lymphoma In this critical study, Keytruda demonstrated a statistically significant clinical improvement in progression-free survival PFS (one of the double major endpoints), and keytruda achieved positive results in Phase 3 clinical trials for the treatment of three-negative breast cancer and Stage III non-small cell lung cancer (NSCLC) , Janssen Pharmaceuticals released the final results of the Key Phase 3 clinical trial sPARTAN of the Erleada ® (apalutamide): In patients with a high risk of metastasis, transverse detonative resistance to prostate cancer (nmCRPC) was significantly improved compared to individual androgen deprivation therapy (ADT) (Sina Pharmaceutical News) Noor and Nord have released the top line results of step4 clinical trial semaglutide(semaglutide) weight loss efficacy PHASE IIIa This is a randomized, double-blind, multicenter, placebo-controlled, withdrawal trial that assesses the efficacy and safety of semaglutide for continuous weight management The 68-week study, which included a 20-week introduction period and a 48-week maintenance period, included a group of 902 obese or overweight patients with comorbidities, and investigated the effects of sematideglu or placebo on weight (Sina Pharma News) U.S biotech company MyoKardia announced that its myocoagulin inhibitor mavacamten (Myk-461) reached the first and all secondary endpoints in a phase III clinical called EXPLORER The trial recruited 251 patients with hypertrophy myocardial disease, with a level 1 endpoint of 30-week oxygen intake and a composite endpoint of disease grade Results mavacamten was significantly better than placebo, with 65 percent of patients in the drug group at least one level, twice as likely as the placebo group The secondary endpoint mavacamten, such as the gradient of the left ventricle outflow and the patient's self-reported quality of life, was also significantly better than the control group 13, clinical stage biotech company Allogene Therapeutics and partner Servier Pharmaceuticals released the first batch of data summary of its allo-tallogeneic CAR-T (AlloCART ™) therapy ALLO-501 and ALLO-647 for the first human research of recurrent/incurable non-Hodgkin lymphoma ALPHA (Sina Pharmaceutical News) Capricor Corporation announced that its development of cardiocellular therapy CAP-1002, in the treatment of advanced Duchenne muscular dystrophy (DMD) patients in the phase 2 clinical trial HOPE-2, significantly improved the upper limbs, heart and respiratory function of patients It is worth noting that this trial is the first to confirm in the treatment of DMD patients that the stability of heart function is associated with a reduction in cell damage biomarkers (Pharmaceutical Ming Kang de) 14, to Ling Pharmaceuticals declared 6.1 class of new Chinese medicine even flower cough tablets approved by the State Drug Administration for the treatment of acute trachea, bronchitis (Pharmaceutical Rubik's Cube) 14, Red Day Pharmaceuticals issued a notice that recently received the State Drug Administration issued under the Iban sodium acid injection drug registration approval Minet data show that in 2019 in China's public medical institutions terminal Iban pyridine sales of more than 800 million yuan, earlier Iban sodium acid injection of domestic approved enterprises reached 7 (Minet) Novartis Tropifexor capsules and LIK066 tablets were approved for clinical use in China for the joint treatment of non-alcoholic fatty hepatitis (Pharmaceutical Rubik's Cube) 13, AstraZeneca in China submitted the Dagrenet Net New Indications Listing Application is intended to be included in the priority review for the use of blood-sagtograde reduced heart failure in adult patients, reduced risk of cardiovascular death and deterioration of heart failure, and improved symptoms of heart failure The condition was approved by the FDA on May 5 The , Bluebird and Baishi Meishi bao announced that they had received a formal response from the FDA in March, rejecting a biologic license application for its multiple myeloma CAR-T treatment, idecabgenevicleu (ide-cel, bb2121), submitted in March Bluebird's shares fell nearly 7 percent in pre-market trading on the back of the bad news (Sina Pharmaceutical News) Anding Medicine and Novocure 13 jointly announced that China's State Drug Administration has approved the tumor electric field treatment Optune (Chinese commodity name: Epshield ®) market application, for the treatment of newly diagnosed glioblastoma patients with temolyne amine treatment, as well as as as a single therapy for relapsed glioblastoma patients Glioblastoma is the most common primary brain tumor, while Epshield ® is the first treatment approved for glioblastoma in mainland China in 15 years (Sina Pharmaceutical News) Goli Pharmaceuticals announced on the 13th that its in-house research and development of the treatment of non-alcoholic fatty hepatitis (NASH) class 1 innovative drug ASC41 clinical trial application was approved by The State Drug Administration of China Pharmaceuticals Inc announced that the FDA has accepted its development of the MC4R agonist setmelanotide to treat new drug applications for patients with opioid-promoted hemisphinand and leprosy receptors (LEPR) defective obesity patients, and also grants them priority review eligibility, and is expected to respond on November 27 this year the Bollinger Ingelham and CDR-Life announced that they have reached a partnership and licensing agreement to jointly develop antibody-based therapies for the treatment of map-like atrophy (GA) GA is a performing, irreversible retinal disease that occurs in age-related macular degeneration (AMD) patients, and there is currently no targeted treatment (American News Agency)